RT Journal Article
SR Electronic
T1 Overlapping Time Scales Obscure Early Warning Signals of the Second COVID-19 Wave
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.27.21261226
DO 10.1101/2021.07.27.21261226
A1 Dablander, Fabian
A1 Heesterbeek, Hans
A1 Borsboom, Denny
A1 Drake, John M.
YR 2021
UL http://medrxiv.org/content/early/2021/08/13/2021.07.27.21261226.abstract
AB Early warning indicators based on critical slowing down have been suggested as a model-independent and low-cost tool to anticipate the (re)emergence of infectious diseases. We studied whether such indicators could reliably have anticipated the second COVID-19 wave in European countries. Contrary to theoretical predictions, we found that characteristic early warning indicators generally decreased rather than increased prior to the second wave. A model explains this unexpected finding as a result of transient dynamics and the multiple time scales of relaxation during a non-stationary epidemic. Particularly, if an epidemic that seems initially contained after a first wave does not fully settle to its new quasi-equilibrium prior to changing circumstances or conditions that force a second wave, then indicators will show a decreasing rather than an increasing trend as a result of the persistent transient trajectory of the first wave. Our simulations show that this lack of time scale separation was to be expected during the second European epidemic wave of COVID-19. Overall, our results emphasize that the theory of critical slowing down applies only when the external forcing of the system across a critical point is slow relative to the internal system dynamics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementF.D. was supported by ZonMw project 10430022010001.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Since we only analyze public COVID-19 data, IRB approval was not needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll COVID-19 data used in this work is publicly available from a number of sources, for example the WHO (https://covid19.who.int/info/).